ZTS:NYE-Zoetis Inc. Class A

EQUITY | Drug Manufacturers | New York Stock Exchange

Last Closing Price

USD 84.59

Change

0.00 (0.00)%

Market Cap

USD 40.64B

Volume

3.06M

Average Target Price

USD 97.20 (14.91%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Zoetis Inc discovers, develops, manufactures & commercializes animal health medicines & vaccines for livestock & companion animals. Its products include anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceutical products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-19 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
JNJ Johnson & Johnson

N/A

USD 350.51B
PFE Pfizer Inc.

N/A

USD 245.84B
NVS Novartis AG

N/A

USD 205.57B
MRK Merck & Company Inc. (new)

N/A

USD 197.29B
ABBV AbbVie Inc.

N/A

USD 134.63B
LLY Eli Lilly and Company

N/A

USD 123.51B
GSK GlaxoSmithKline PLC

N/A

USD 96.96B
AZN Astrazeneca PLC

N/A

USD 92.62B
BMY Bristol-Myers Squibb Company

N/A

USD 81.82B
TAK Takeda Pharmaceutical Company ..

N/A

USD 61.38B

ETFs Containing ZTS

DXG:CA Dynamic iShares Active Gl.. 9.58 % 0.91 %

N/A

CAD 0.20B
DXU:CA Dynamic iShares Active U... 9.26 % 0.89 %

N/A

CAD 0.17B
MOO VanEck Vectors Agribusine.. 7.83 % 0.54 %

N/A

USD 0.76B
IHE iShares U.S. Pharmaceutic.. 4.90 % 0.43 %

N/A

USD 0.39B
XPH SPDR S&P Pharmaceuticals 4.77 % 0.35 %

N/A

USD 0.25B
FTXH First Trust Nasdaq Pharma.. 4.12 % 0.60 %

N/A

USD 4.09M
WBIL WBI BullBear Quality 1000 3.59 % 1.04 %

N/A

USD 0.03B
PPH VanEck Vectors Pharmaceut.. 0.00 % 0.36 %

N/A

USD 0.24B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.11% 27% F 6% F
Dividend Return 0.19% 33% F 6% F
Total Return -0.92% 27% F 7% F
Trailing 12 Months  
Capital Gain 10.40% 84% B 90% A-
Dividend Return 0.71% 8% F 10% F
Total Return 11.11% 84% B 89% B+
Trailing 5 Years  
Capital Gain 166.59% 100% A+ 97% A+
Dividend Return 6.58% 27% F 21% F
Total Return 173.17% 100% A+ 97% A+
Average Annual (5 Year Horizon)  
Capital Gain 27.29% 100% A+ 95% A
Dividend Return 28.13% 100% A+ 95% A
Total Return 0.84% 33% F 18% F
Risk Return Profile  
Volatility (Standard Deviation) 19.08% 53% F 38% F
Risk Adjusted Return 147.47% 100% A+ 96% A
Market Capitalization 24.45B 58% F 96% A

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 35.39 35% F 15% F
Price/Book Ratio 20.63 4% F 3% F
Price / Cash Flow Ratio 5.70 12% F 18% F
Price/Free Cash Flow Ratio 26.77 23% F 19% F
Management Effectiveness  
Return on Equity 59.55% 92% A- 96% A
Return on Invested Capital 26.84% 88% B+ 90% A-
Return on Assets 12.81% 96% A 92% A-
Debt to Equity Ratio 272.25% 12% F 11% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.